Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, and AbbVie. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$788.62 -29.60 (-3.62%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$782.89 -5.73 (-0.73%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The stock has a strong "Moderate Buy" consensus rating from analysts, indicating positive sentiment and potential for growth.
  • Recent price target upgrades from major financial institutions, such as Wells Fargo raising it to $1,100.00, suggest confidence in the company's future performance.
  • Eli Lilly and Co's current stock price is $820.30, which may present a buying opportunity given the higher price targets set by analysts.

Cons of Eli Lilly and Company

  • The stock has experienced a slight decline of 0.2%, indicating potential volatility and uncertainty in the short term.
  • Recent earnings report showed an EPS of $5.32, which missed the consensus estimate of $5.45, raising concerns about the company's short-term profitability.
  • With a high P/E ratio of 70.05, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$747.75 billion
P/E Ratio
67.35
Consensus Rating
Moderate Buy
Consensus Price Target
$1,009.72 (+28.0% Upside)
Volume
2.67 million shares
Average Volume
3.30 million shares
Today's Range
$787.06
$818.79
50-Day Range
$784.78
$930.22
52-Week Range
$711.40
$972.53
Dividend Yield
0.73%
UnitedHealth Group stock logo

2. UnitedHealth Group NYSE:UNH

$540.87 +17.67 (+3.38%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$535.95 -4.92 (-0.91%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group has a strong market capitalization of $471.51 billion, indicating its significant presence and stability in the healthcare sector.
  • The current stock price is $515.47, which reflects a solid performance and potential for growth, especially considering its 1-year high of $630.73.
  • Institutional investors own 87.86% of the stock, suggesting strong confidence from major financial entities in the company's future prospects.

Cons of UnitedHealth Group

  • The company has a debt-to-equity ratio of 0.74, which, while manageable, indicates that it has a significant amount of debt compared to its equity, potentially posing risks in economic downturns.
  • UnitedHealth Group's stock has experienced volatility, with a 1-year low of $436.38, suggesting that there may be fluctuations that could impact short-term investors.
  • The current ratio of 0.83 indicates that the company may have liquidity issues, as it has less current assets than current liabilities, which could affect its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$494.74 billion
P/E Ratio
34.89
Consensus Rating
Buy
Consensus Price Target
$629.32 (+16.4% Upside)
Volume
6.45 million shares
Average Volume
4.23 million shares
Today's Range
$529.29
$548.50
50-Day Range
$461.09
$548.65
52-Week Range
$436.38
$630.73
Dividend Yield
1.63%
Johnson & Johnson stock logo

3. Johnson & Johnson NYSE:JNJ

$159.90 +4.54 (+2.92%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$159.12 -0.78 (-0.49%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price of Johnson & Johnson is $163.63, which reflects a stable market position and potential for growth.
  • Analysts have a consensus rating of "Moderate Buy" for Johnson & Johnson, indicating positive sentiment and potential upside in the stock's value.
  • Recent upgrades from major financial institutions, such as Bank of America raising their target price to $171.00, suggest confidence in the company's future performance.

Cons of Johnson & Johnson

  • Recent price target cuts from Wells Fargo & Company and Stifel Nicolaus indicate some analysts are cautious about the stock's near-term performance.
  • Insider selling activity, such as the recent sale of shares by VP Robert J. Decker, may raise concerns about the company's future prospects from those within the organization.
  • The stock has experienced fluctuations, with a 52-week low of $140.68, suggesting potential volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$385.33 billion
P/E Ratio
24.04
Consensus Rating
Moderate Buy
Consensus Price Target
$171.33 (+7.2% Upside)
Volume
13.24 million shares
Average Volume
7.73 million shares
Today's Range
$157.48
$160.65
50-Day Range
$146.76
$167.57
52-Week Range
$140.68
$169.99
Dividend Yield
3.04%
AbbVie stock logo

4. AbbVie NYSE:ABBV

$201.31 -3.88 (-1.89%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$199.75 -1.56 (-0.78%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie offers a strong dividend yield of 3.20%, providing a reliable income stream for investors. The annualized dividend of $6.56 reflects the company's commitment to returning value to shareholders.
  • The company has a diverse portfolio of innovative products, including the latest treatments like Rinvoq for various autoimmune conditions and Skyrizi for plaque psoriasis, which are driving growth and market share.
  • AbbVie has a robust pipeline of new therapies, which could lead to significant revenue growth in the coming years, enhancing its long-term investment appeal.

Cons of AbbVie

  • The high payout ratio of 273.33% raises concerns about the sustainability of the dividend, as it suggests that the company is paying out more in dividends than it earns, which could lead to future cuts.
  • AbbVie faces significant competition in the pharmaceutical market, particularly for its key products, which could impact its market share and profitability.
  • Regulatory challenges and potential delays in the approval of new drugs could hinder AbbVie's growth prospects and affect investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$356.11 billion
P/E Ratio
83.88
Consensus Rating
Moderate Buy
Consensus Price Target
$211.45 (+5.0% Upside)
Volume
7.59 million shares
Average Volume
5.75 million shares
Today's Range
$201.24
$210.69
50-Day Range
$170.05
$216.62
52-Week Range
$153.58
$218.66
Dividend Yield
3.20%
Novo Nordisk A/S stock logo

5. Novo Nordisk A/S NYSE:NVO

$67.08 -1.16 (-1.70%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$64.91 -2.17 (-3.24%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Strong financial performance with a recent earnings per share (EPS) of $0.91, exceeding expectations, indicating robust profitability.
  • Market capitalization of $311.23 billion, showcasing the company's significant size and stability in the pharmaceutical sector.
  • Recent upgrades from analysts, including a "strong-buy" rating from BNP Paribas, suggesting positive market sentiment and potential for stock appreciation.

Cons of Novo Nordisk A/S

  • Recent decline in stock price from a one-year high of $148.15, indicating potential volatility and investor uncertainty.
  • Debt-to-equity ratio of 0.62, which, while manageable, suggests that the company has a moderate level of debt that could impact financial flexibility.
  • Current ratio of 0.74, indicating that the company may face challenges in meeting short-term liabilities, which could raise concerns for liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$301.04 billion
P/E Ratio
20.39
Consensus Rating
Moderate Buy
Consensus Price Target
$145.25 (+116.5% Upside)
Volume
8.82 million shares
Average Volume
5.59 million shares
Today's Range
$67.00
$68.54
50-Day Range
$67.08
$90.94
52-Week Range
$65.20
$148.15
Dividend Yield
1.03%
Remove Ads
Novartis stock logo

6. Novartis NYSE:NVS

$112.37 +1.60 (+1.44%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$109.02 -3.35 (-2.98%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG's stock is currently trading at $111.46, showing a recent increase of 1.2%, which may indicate positive market sentiment and potential for further growth.
  • The company has a strong market capitalization of approximately $227.82 billion, suggesting stability and the ability to invest in research and development for new products.
  • Recent analyst upgrades, including a "strong-buy" rating from StockNews.com, reflect growing confidence in the company's future performance.

Cons of Novartis

  • Several analysts have issued "underweight" ratings, including Morgan Stanley and Barclays, which may indicate concerns about the company's growth prospects.
  • American Century Companies Inc. recently reduced its position in Novartis AG by 11.0%, suggesting that some institutional investors may be losing confidence in the stock.
  • The stock has experienced fluctuations, with a 52-week low of $92.35, indicating potential volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$229.68 billion
P/E Ratio
19.11
Consensus Rating
Reduce
Consensus Price Target
$123.38 (+9.8% Upside)
Volume
2.93 million shares
Average Volume
1.51 million shares
Today's Range
$112.26
$114.44
50-Day Range
$99.93
$115.60
52-Week Range
$92.35
$120.92
Dividend Yield
2.26%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$131.57 -0.36 (-0.27%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$130.19 -1.38 (-1.05%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories has received multiple "buy" ratings from analysts, indicating strong confidence in the stock's potential for growth.
  • The current stock price is approximately $130.81, which is near its 50-day moving average of $130.05, suggesting stability in its recent performance.
  • Analysts have set a consensus target price of $137.94, which represents a potential upside for investors based on current trading levels.

Cons of Abbott Laboratories

  • Insider selling activity has been noted, with executives selling significant shares, which may raise concerns about their confidence in the company's future performance.
  • The stock has a relatively high P/E ratio of 17.10, which could indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite a strong market position, Abbott Laboratories faces competition in the healthcare sector, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.19 billion
P/E Ratio
17.20
Consensus Rating
Moderate Buy
Consensus Price Target
$137.94 (+4.8% Upside)
Volume
6.24 million shares
Average Volume
5.86 million shares
Today's Range
$131.48
$133.64
50-Day Range
$125.12
$140.13
52-Week Range
$99.71
$141.23
Dividend Yield
1.80%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$73.92 +1.70 (+2.35%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$72.26 -1.66 (-2.24%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • AstraZeneca has received multiple upgrades from analysts, including a recent upgrade from UBS Group from "neutral" to "buy," indicating strong market confidence in the company's future performance.
  • The stock currently trades at approximately $73.79, reflecting a solid market capitalization of around $228.84 billion, which suggests a stable investment opportunity.
  • Recent institutional investments show a growing interest in AstraZeneca, with Foundation Wealth Management LLC acquiring 38,376 shares, indicating confidence from significant investors.

Cons of AstraZeneca

  • GQG Partners LLC recently reduced its holdings in AstraZeneca by 20.1%, which may signal a lack of confidence from some institutional investors.
  • The stock has experienced fluctuations, with a 12-month low of $62.75, indicating potential volatility that could concern risk-averse investors.
  • Despite positive analyst ratings, the company faces significant competition in the pharmaceutical industry, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$223.97 billion
P/E Ratio
32.71
Consensus Rating
Buy
Consensus Price Target
$89.75 (+21.4% Upside)
Volume
9.15 million shares
Average Volume
5.11 million shares
Today's Range
$73.87
$75.70
50-Day Range
$68.96
$77.96
52-Week Range
$62.75
$87.68
Dividend Yield
2.84%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$86.32 -0.28 (-0.32%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$85.70 -0.62 (-0.72%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck's stock is currently trading at $89.18, which is a reasonable entry point considering its one-year high of $134.63, indicating potential for price appreciation.
  • The company has a strong market capitalization of $225.27 billion, reflecting its stability and ability to weather market fluctuations.
  • Merck has a low PE ratio of 13.25, suggesting that the stock may be undervalued compared to its earnings, making it an attractive option for value investors.

Cons of Merck & Co., Inc.

  • Schroder Investment Management Group recently reduced its holdings by 22.3%, which may indicate a lack of confidence in the stock's short-term performance.
  • The stock has experienced a decline from its 200-day moving average price of $100.10, suggesting a potential downward trend that could concern investors.
  • Merck's beta of 0.35 indicates lower volatility compared to the market, which may limit potential high returns for aggressive investors seeking growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.05 billion
P/E Ratio
12.83
Consensus Rating
Moderate Buy
Consensus Price Target
$117.12 (+35.7% Upside)
Volume
12.68 million shares
Average Volume
11.10 million shares
Today's Range
$86.26
$88.90
50-Day Range
$83.01
$99.79
52-Week Range
$81.04
$134.63
Dividend Yield
3.61%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$469.88 -19.18 (-3.92%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$467.26 -2.62 (-0.56%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. has a strong market capitalization of approximately $187.89 billion, indicating a robust financial position and stability in the market.
  • The company has shown consistent growth, with institutional investors owning about 89.23% of its stock, reflecting confidence from major financial entities.
  • Recent insider trading activity suggests confidence in the company's future, with executives actively managing their shares, although some have sold portions of their holdings.

Cons of Thermo Fisher Scientific

  • Insider selling activity has been notable, with a total of 23,900 shares sold worth $13,106,062 in the last quarter, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a recent trading volume of 2,060,693 shares, indicating potential volatility that could affect investor sentiment.
  • The price-to-earnings (PE) ratio stands at 30.13, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$177.27 billion
P/E Ratio
28.43
Consensus Rating
Moderate Buy
Consensus Price Target
$653.23 (+39.0% Upside)
Volume
2.81 million shares
Average Volume
1.63 million shares
Today's Range
$468.17
$485.91
50-Day Range
$469.88
$607.06
52-Week Range
$467.26
$627.88
Dividend Yield
0.34%
Remove Ads
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$494.61 -12.44 (-2.45%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$488.30 -6.31 (-1.28%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Recent analyst upgrades have increased price targets significantly, with Citigroup raising its target from $640.00 to $711.00, indicating strong market confidence in the company's growth potential.
  • The stock currently has a price of approximately $556.28, which is below many analysts' target prices, suggesting potential for price appreciation.
  • Intuitive Surgical, Inc. has a strong reputation in the market for its innovative surgical systems, which enhance minimally invasive procedures, potentially leading to increased demand and revenue growth.

Cons of Intuitive Surgical

  • Insider sales have been substantial, with over 33,000 shares sold recently, which may indicate a lack of confidence in the stock's short-term performance.
  • Some analysts have downgraded their ratings, such as Erste Group Bank lowering its rating from "strong-buy" to "hold," which could signal caution among investors.
  • The stock has experienced a significant decrease in insider ownership, with some executives reducing their stakes by over 60%, which may raise concerns about future company performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$176.17 billion
P/E Ratio
77.16
Consensus Rating
Moderate Buy
Consensus Price Target
$611.86 (+23.7% Upside)
Volume
2.73 million shares
Average Volume
1.53 million shares
Today's Range
$484.88
$504.09
50-Day Range
$476.78
$608.48
52-Week Range
$364.17
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$309.85 +4.15 (+1.36%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$308.12 -1.74 (-0.56%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has a strong consensus price target of $314.04, indicating potential for price appreciation from the current stock price of $306.95.
  • The company has received multiple positive ratings from analysts, including a "strong buy" rating, which suggests confidence in its future performance.
  • Amgen Inc. has a solid market capitalization of $164.90 billion, reflecting its stability and ability to invest in growth opportunities.

Cons of Amgen

  • The company has a high debt-to-equity ratio of 9.62, which may raise concerns about financial leverage and the ability to manage debt effectively.
  • Amgen Inc. has experienced a significant decrease in insider ownership, with executives selling a total of 69,341 shares recently, which could signal a lack of confidence in the company's future.
  • Despite a strong market position, the stock has faced volatility, with a one-year low of $253.30, indicating potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$166.45 billion
P/E Ratio
41.04
Consensus Rating
Hold
Consensus Price Target
$314.04 (+1.4% Upside)
Volume
3.28 million shares
Average Volume
2.70 million shares
Today's Range
$306.70
$314.90
50-Day Range
$275.42
$327.36
52-Week Range
$253.30
$346.85
Dividend Yield
3.10%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$98.51 -1.54 (-1.54%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$97.64 -0.87 (-0.88%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Boston Scientific Co. has received multiple upgrades from analysts, with price targets raised to as high as $115.00, indicating strong market confidence in the company's growth potential.
  • The stock currently trades at $99.29, which is near its 52-week high of $107.17, suggesting that it is performing well and may continue to appreciate in value.
  • With a consensus rating of "Moderate Buy" from analysts, the majority view is positive, which can be a strong indicator for potential investors.

Cons of Boston Scientific

  • The stock has a high price-to-earnings (P/E) ratio of 79.43, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been notable, with executives selling a significant number of shares, which could indicate a lack of confidence in the stock's short-term performance.
  • Despite strong earnings, the company's net margin of 11.07% may be lower than industry peers, raising concerns about its competitive position.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.70 billion
P/E Ratio
78.80
Consensus Rating
Buy
Consensus Price Target
$108.91 (+10.6% Upside)
Volume
11.00 million shares
Average Volume
6.09 million shares
Today's Range
$96.65
$99.86
50-Day Range
$93.79
$106.20
52-Week Range
$66.80
$107.17
Dividend Yield
N/A
Danaher stock logo

14. Danaher NYSE:DHR

$197.75 -7.41 (-3.61%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$195.70 -2.06 (-1.04%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. recently increased its quarterly dividend from $0.27 to $0.32 per share, reflecting a commitment to returning value to shareholders. This increase represents an annualized dividend of $1.28, providing a yield of 0.62%, which can be attractive for income-focused investors.
  • The company has shown strong earnings performance, reporting $2.14 earnings per share for the latest quarter, which met analysts' expectations. This consistency in earnings can indicate financial stability and growth potential.
  • Danaher Co. has a solid market capitalization of $147.01 billion, which positions it as a significant player in its industry, potentially offering more stability compared to smaller companies.

Cons of Danaher

  • The stock has a relatively high P/E ratio of 38.96, which may suggest that it is overvalued compared to its earnings. This could lead to a price correction if earnings do not grow as expected.
  • Analysts have recently adjusted their price targets downward, with some estimates dropping from $299.00 to $277.00, indicating a potential lack of confidence in the stock's near-term performance.
  • Danaher Co. has a PEG ratio of 2.66, which is considered high. This ratio compares the P/E ratio to the company's growth rate, and a high PEG can indicate that the stock may not be a good value relative to its growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$141.33 billion
P/E Ratio
37.45
Consensus Rating
Moderate Buy
Consensus Price Target
$278.24 (+40.7% Upside)
Volume
5.41 million shares
Average Volume
3.20 million shares
Today's Range
$197.50
$204.58
50-Day Range
$197.75
$250.51
52-Week Range
$195.70
$281.70
Dividend Yield
0.62%
Stryker stock logo

15. Stryker NYSE:SYK

$368.12 -9.34 (-2.47%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$364.99 -3.13 (-0.85%)
As of 06:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. recently reported earnings per share (EPS) of $4.01, exceeding the consensus estimate of $3.87, indicating strong financial performance and potential for growth.
  • The company has a solid market capitalization of $141.12 billion, reflecting its stability and prominence in the medical technology sector.
  • With a current stock price of $372.19, Stryker Co. is trading near its one-year high of $406.19, suggesting positive market sentiment and potential for further appreciation.

Cons of Stryker

  • The company's P/E ratio stands at 47.60, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Stryker Co. has a debt-to-equity ratio of 0.59, which, while manageable, suggests that the company is using a moderate amount of debt to finance its operations, posing risks in a rising interest rate environment.
  • Recent insider selling, including a significant transaction by Director Ronda E. Stryker, may raise concerns about the confidence of insiders in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.51 billion
P/E Ratio
47.44
Consensus Rating
Moderate Buy
Consensus Price Target
$421.90 (+14.6% Upside)
Volume
3.31 million shares
Average Volume
1.30 million shares
Today's Range
$361.59
$374.56
50-Day Range
$363.52
$399.83
52-Week Range
$314.93
$406.19
Dividend Yield
0.92%
Remove Ads
Gilead Sciences stock logo

16. Gilead Sciences NASDAQ:GILD

$112.39 +0.50 (+0.45%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$112.02 -0.37 (-0.33%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. recently reported a quarterly earnings per share (EPS) of $1.90, exceeding analysts' expectations of $1.67, indicating strong financial performance and potential for growth.
  • The company has increased its quarterly dividend to $0.79 per share, up from $0.77, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend of $3.16, providing a dividend yield of 2.83%.
  • With a return on equity of 31.63%, Gilead Sciences, Inc. demonstrates effective management and profitability, which can be attractive to investors looking for companies that efficiently utilize shareholder equity.

Cons of Gilead Sciences

  • The company's payout ratio is exceptionally high at 854.05%, which may raise concerns about sustainability in dividend payments, especially if earnings do not continue to grow.
  • Insider selling has been noted, with significant shares sold by the CFO, which could indicate a lack of confidence in the stock's short-term performance.
  • Despite recent upgrades, the stock has a mixed rating from analysts, with a consensus rating of "Moderate Buy," suggesting that not all analysts are optimistic about its future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.94 billion
P/E Ratio
303.76
Consensus Rating
Moderate Buy
Consensus Price Target
$105.12 (-6.5% Downside)
Volume
10.04 million shares
Average Volume
7.30 million shares
Today's Range
$112.28
$114.75
50-Day Range
$93.07
$117.41
52-Week Range
$62.07
$119.96
Dividend Yield
2.82%
Sanofi stock logo

17. Sanofi NASDAQ:SNY

$54.62 +0.67 (+1.24%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$53.80 -0.82 (-1.50%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi's stock is currently trading at $58.92, showing a positive trend in recent trading sessions, which may indicate investor confidence and potential for growth.
  • The company has received a consensus rating of "Buy" from analysts, with a target price of $60.00, suggesting that there is expected upside in the stock price.
  • Recent upgrades from analysts, including a "strong-buy" rating from Sanford C. Bernstein, reflect positive sentiment and potential for increased market performance.

Cons of Sanofi

  • Despite recent positive ratings, the stock has a relatively high P/E ratio of 23.66, which may indicate that it is overvalued compared to its earnings.
  • Sanofi's stock has experienced volatility, with a 52-week low of $45.22, suggesting potential risks for investors if the stock price declines again.
  • The company has a beta of 0.58, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$138.62 billion
P/E Ratio
21.94
Consensus Rating
Buy
Consensus Price Target
$62.50 (+14.4% Upside)
Volume
1.84 million shares
Average Volume
2.27 million shares
Today's Range
$54.58
$55.77
50-Day Range
$52.37
$59.42
52-Week Range
$45.22
$60.12
Dividend Yield
2.69%
Pfizer stock logo

18. Pfizer NYSE:PFE

$24.30 -0.41 (-1.64%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$24.20 -0.09 (-0.37%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently reported earnings per share of $0.63, exceeding analysts' expectations of $0.48, indicating strong financial performance and effective management.
  • The company has shown a significant year-over-year revenue increase of 24.7%, reflecting robust demand for its biopharmaceutical products.
  • Pfizer Inc. has a current stock price of $24.97, which is near its 12-month low of $24.48, potentially offering a buying opportunity for investors looking for value.

Cons of Pfizer

  • Despite recent positive earnings, the stock has experienced volatility, with a 12-month high of $31.54, suggesting potential risks associated with price fluctuations.
  • Some analysts have downgraded their price targets for Pfizer Inc., with Citigroup lowering its target from $30.00 to $29.00, indicating a cautious outlook.
  • The company has a debt-to-equity ratio of 0.63, which, while manageable, indicates that it has a moderate level of debt that could impact financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$137.79 billion
P/E Ratio
17.23
Consensus Rating
Moderate Buy
Consensus Price Target
$31.92 (+31.4% Upside)
Volume
53.41 million shares
Average Volume
39.15 million shares
Today's Range
$24.28
$24.87
50-Day Range
$24.30
$26.89
52-Week Range
$24.21
$31.54
Dividend Yield
6.88%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$484.01 +0.52 (+0.11%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$474.50 -9.51 (-1.96%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated has a strong market capitalization of $126.52 billion, indicating a robust financial position and potential for growth.
  • The company reported a recent earnings per share (EPS) of $3.54, which, despite missing estimates, reflects ongoing revenue generation in a competitive market.
  • With a current stock price of $492.69, investors may find the stock appealing given its recent performance and potential for future appreciation.

Cons of Vertex Pharmaceuticals

  • The company has a negative net margin of 4.86%, indicating that it is currently spending more than it earns, which could raise concerns about profitability.
  • Vertex Pharmaceuticals Incorporated has a P/E ratio of -223.95, suggesting that the company is not currently profitable, which may deter risk-averse investors.
  • Recent insider selling, including a significant transaction by an executive vice president, may signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$124.29 billion
P/E Ratio
-220.00
Consensus Rating
Moderate Buy
Consensus Price Target
$509.17 (+5.2% Upside)
Volume
2.06 million shares
Average Volume
1.28 million shares
Today's Range
$480.01
$494.49
50-Day Range
$438.40
$513.76
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Bristol-Myers Squibb stock logo

20. Bristol-Myers Squibb NYSE:BMY

$57.70 -1.90 (-3.18%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$57.05 -0.66 (-1.14%)
As of 06:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • Bristol-Myers Squibb reported an EPS of $1.67 for the latest quarter, exceeding analysts' expectations of $1.47, indicating strong financial performance and potential for growth.
  • The company has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • With a current stock price around $54.84, there is potential for appreciation, especially given the positive analyst ratings and target price increases from firms like Jefferies and Citigroup.

Cons of Bristol-Myers Squibb

  • The company has a negative net margin of 18.53%, which indicates that it is currently spending more than it earns, raising concerns about profitability.
  • Insider ownership is relatively low at 0.09%, which may suggest a lack of confidence from executives in the company's future performance.
  • Despite recent upgrades in ratings, there are still two analysts who have rated the stock as a sell, indicating some skepticism about its future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$117.42 billion
P/E Ratio
-13.06
Consensus Rating
Hold
Consensus Price Target
$57.86 (+0.3% Upside)
Volume
13.23 million shares
Average Volume
12.70 million shares
Today's Range
$57.66
$60.80
50-Day Range
$53.85
$63.00
52-Week Range
$39.35
$63.33
Dividend Yield
4.21%
Remove Ads
Medtronic stock logo

21. Medtronic NYSE:MDT

$87.89 -0.97 (-1.10%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$87.00 -0.89 (-1.01%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc reported earnings per share of $1.39 for the latest quarter, exceeding the consensus estimate of $1.36, indicating strong financial performance and effective management.
  • The company has a solid return on equity of 14.07%, which reflects its ability to generate profits from shareholders' equity, a positive sign for potential investors.
  • Medtronic plc recently declared a quarterly dividend of $0.70 per share, translating to an annualized dividend of $2.80 and a yield of 3.15%, providing a steady income stream for investors.

Cons of Medtronic

  • Despite beating earnings estimates, Medtronic plc's revenue of $8.29 billion fell short of the consensus estimate of $8.33 billion, which may raise concerns about future growth prospects.
  • The company's dividend payout ratio is currently at 85.11%, which indicates that a significant portion of earnings is being paid out as dividends, potentially limiting funds available for reinvestment in growth initiatives.
  • Recent insider selling, including a significant transaction by an executive vice president, may signal a lack of confidence in the company's short-term performance, which could deter potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$112.72 billion
P/E Ratio
26.71
Consensus Rating
Hold
Consensus Price Target
$96.07 (+9.3% Upside)
Volume
7.66 million shares
Average Volume
6.56 million shares
Today's Range
$87.69
$89.54
50-Day Range
$86.05
$94.58
52-Week Range
$75.96
$96.25
Dividend Yield
3.15%
Elevance Health stock logo

22. Elevance Health NYSE:ELV

$452.70 +23.37 (+5.44%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$458.62 +5.92 (+1.31%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$102.48 billion
P/E Ratio
17.68
Consensus Rating
Moderate Buy
Consensus Price Target
$519.81 (+14.8% Upside)
Volume
3.31 million shares
Average Volume
1.40 million shares
Today's Range
$433.91
$454.46
50-Day Range
$382.46
$452.70
52-Week Range
$362.21
$567.26
Dividend Yield
1.57%
The Cigna Group stock logo

23. The Cigna Group NYSE:CI

$338.76 +6.84 (+2.06%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$334.70 -4.07 (-1.20%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The Cigna Group recently declared a quarterly dividend of $1.51, which is an increase from the previous $1.40, indicating a commitment to returning value to shareholders.
  • The company has a strong return on equity of 18.61%, suggesting effective management and profitability relative to shareholder equity.
  • Current stock price is $324.74, which reflects a stable market position and potential for growth, especially considering the company's market cap of $88.88 billion.

Cons of The Cigna Group

  • The Cigna Group reported an EPS of $6.64 for the last quarter, missing analysts' expectations of $7.84, which may raise concerns about its short-term performance.
  • Insider selling activity has been notable, with significant shares sold by executives, which could signal a lack of confidence in the company's near-term prospects.
  • The company's net margin is relatively low at 1.39%, indicating that profitability may be constrained compared to competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.71 billion
P/E Ratio
27.68
Consensus Rating
Buy
Consensus Price Target
$373.25 (+10.2% Upside)
Volume
2.40 million shares
Average Volume
1.65 million shares
Today's Range
$329.96
$342.57
50-Day Range
$282.42
$338.76
52-Week Range
$262.03
$370.83
Dividend Yield
1.86%
McKesson stock logo

24. McKesson NYSE:MCK

$716.71 +23.18 (+3.34%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$726.56 +9.85 (+1.37%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. has a strong market capitalization of $83.52 billion, indicating a robust financial position and stability in the healthcare sector.
  • The stock is currently trading at $668.25, which is close to its 52-week high of $672.00, suggesting strong investor confidence and potential for further growth.
  • With a price-to-earnings (P/E) ratio of 30.51, McKesson Co. is positioned for growth, as this ratio indicates how much investors are willing to pay for each dollar of earnings, reflecting positive market sentiment.

Cons of McKesson

  • The company reported a negative return on equity of 181.26%, which indicates that it is not generating profit from its equity, raising concerns about its financial efficiency.
  • McKesson Co. missed analysts' consensus estimates for EPS by $0.57 in its latest quarterly earnings report, which may signal potential challenges in meeting future earnings expectations.
  • Insider selling activity has been notable, with the CEO selling 8,961 shares recently, which could indicate a lack of confidence in the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$86.92 billion
P/E Ratio
32.82
Consensus Rating
Moderate Buy
Consensus Price Target
$661.00 (-7.8% Downside)
Volume
2.21 million shares
Average Volume
844,432 shares
Today's Range
$696.50
$725.00
50-Day Range
$591.47
$716.71
52-Week Range
$464.42
$726.56
Dividend Yield
0.42%
HCA Healthcare stock logo

25. HCA Healthcare NYSE:HCA

$349.03 +2.00 (+0.58%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$347.14 -1.88 (-0.54%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. recently increased its quarterly dividend from $0.66 to $0.72, reflecting a commitment to returning value to shareholders. This increase indicates strong financial health and a positive outlook for future earnings.
  • The company reported earnings per share (EPS) of $6.22, surpassing the consensus estimate of $6.03, which demonstrates robust operational performance and effective cost management.
  • HCA Healthcare, Inc. has a high return on equity (ROE) of 586.47%, indicating that the company is highly efficient in generating profits from its equity investments, which is attractive to investors looking for strong returns.

Cons of HCA Healthcare

  • Despite the positive earnings report, the stock has seen price target reductions from several analysts, indicating a cautious outlook and potential volatility in the stock price.
  • The dividend payout ratio (DPR) is 13.11%, which, while sustainable, suggests that a significant portion of earnings is retained for reinvestment rather than distributed to shareholders, potentially limiting immediate returns.
  • One analyst has issued a sell rating on the stock, which could signal underlying concerns about the company's future performance or market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.93 billion
P/E Ratio
15.89
Consensus Rating
Moderate Buy
Consensus Price Target
$385.67 (+10.5% Upside)
Volume
1.95 million shares
Average Volume
1.35 million shares
Today's Range
$345.12
$353.35
50-Day Range
$305.79
$349.03
52-Week Range
$289.98
$417.14
Dividend Yield
0.84%
Remove Ads
CVS Health stock logo

26. CVS Health NYSE:CVS

$67.44 -0.63 (-0.93%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$66.88 -0.56 (-0.83%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has recently seen a significant increase in institutional investment, with 80.66% of its stock owned by institutional investors, indicating strong confidence in the company's future performance.
  • The stock price is currently around $66.70, which is near the higher end of its one-year range of $43.56 to $79.98, suggesting potential for growth as it approaches its previous highs.
  • Analysts have a consensus rating of "Moderate Buy" for CVS Health Co., with an average price target of $70.39, indicating that many experts believe the stock is undervalued and has room for appreciation.

Cons of CVS Health

  • The company has a relatively high debt-to-equity ratio of 0.80, which may indicate that it is relying on debt to finance its operations, potentially increasing financial risk.
  • Despite recent positive earnings, CVS Health Co. has a net margin of only 1.24%, suggesting that profitability may be constrained, which could limit future growth opportunities.
  • Recent insider trading activity shows that a senior vice president sold a significant number of shares, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.03 billion
P/E Ratio
18.43
Consensus Rating
Moderate Buy
Consensus Price Target
$70.41 (+4.4% Upside)
Volume
12.20 million shares
Average Volume
11.49 million shares
Today's Range
$65.59
$69.18
50-Day Range
$53.95
$68.71
52-Week Range
$43.56
$75.27
Dividend Yield
3.94%
GSK stock logo

27. GSK NYSE:GSK

$39.03 +1.39 (+3.69%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$37.70 -1.33 (-3.42%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc has recently received a "strong-buy" rating from StockNews.com, indicating strong confidence from analysts in the company's future performance.
  • The stock is currently trading at $38.28, which is near its 1-year high of $45.93, suggesting potential for growth as it approaches previous highs.
  • Institutional investors own 15.74% of GSK plc's stock, which can indicate stability and confidence in the company's long-term prospects.

Cons of GSK

  • The stock has experienced fluctuations, with a recent trading down of 0.8%, which may indicate volatility and uncertainty in the market.
  • GSK plc has a P/E ratio of 24.08, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
  • Despite recent positive ratings, seven analysts have rated the stock with a hold rating, indicating caution among some market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.78 billion
P/E Ratio
24.55
Consensus Rating
Moderate Buy
Consensus Price Target
$43.25 (+10.8% Upside)
Volume
10.94 million shares
Average Volume
4.49 million shares
Today's Range
$38.47
$39.18
50-Day Range
$34.29
$40.41
52-Week Range
$31.72
$45.93
Dividend Yield
4.06%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$159.34 -4.16 (-2.54%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$158.30 -1.04 (-0.65%)
As of 05:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has received multiple upgrades from analysts, with Piper Sandler raising their target price to $205.00 and StockNews.com upgrading their rating to "buy," indicating strong market confidence in the company's future performance.
  • The average target price for Zoetis Inc. is currently $215.90, suggesting potential upside for investors based on current trading levels.
  • As of now, the stock price is $163.03, which is below the average target price, presenting a buying opportunity for investors looking for growth.

Cons of Zoetis

  • Recent insider selling, including a director selling 1,210 shares, may raise concerns about the company's future prospects and could indicate a lack of confidence from those within the company.
  • The stock has experienced a decline of 1.2% recently, which may suggest volatility and potential challenges in maintaining its current price level.
  • With a price-to-earnings ratio of 29.80, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$73.21 billion
P/E Ratio
29.13
Consensus Rating
Buy
Consensus Price Target
$215.90 (+35.5% Upside)
Volume
3.28 million shares
Average Volume
2.59 million shares
Today's Range
$159.26
$166.34
50-Day Range
$156.43
$175.65
52-Week Range
$144.80
$200.33
Dividend Yield
1.24%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$610.64 -14.96 (-2.39%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$609.50 -1.14 (-0.19%)
As of 06:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. reported a strong quarterly earnings per share (EPS) of $12.07, exceeding analysts' expectations of $11.21, indicating robust financial performance and effective management.
  • The company has a solid market capitalization of $69.33 billion, reflecting its significant presence and stability in the biopharmaceutical sector.
  • With a net margin of 31.07%, Regeneron Pharmaceuticals, Inc. demonstrates efficient cost management and profitability, which can lead to higher returns for investors.

Cons of Regeneron Pharmaceuticals

  • Despite recent successes, the stock has seen target price reductions from several brokerages, indicating potential concerns about future growth and profitability.
  • The price-to-earnings-growth (P/E/G) ratio of 2.34 suggests that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
  • Regeneron Pharmaceuticals, Inc. has a relatively low dividend yield of 0.56%, which may not attract income-focused investors looking for higher returns from dividends.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$66.76 billion
P/E Ratio
15.95
Consensus Rating
Moderate Buy
Consensus Price Target
$966.88 (+58.3% Upside)
Volume
1.05 million shares
Average Volume
679,432 shares
Today's Range
$607.88
$628.00
50-Day Range
$610.64
$744.83
52-Week Range
$607.88
$1,211.20
Dividend Yield
0.14%
Becton, Dickinson and Company stock logo

30. Becton, Dickinson and Company NYSE:BDX

$221.59 -4.83 (-2.13%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$221.11 -0.48 (-0.22%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company recently reported earnings per share (EPS) of $3.43, exceeding analysts' expectations of $3.00, indicating strong financial performance.
  • Becton, Dickinson and Company has initiated a share repurchase program, allowing the company to buy back 10 million shares, which often signals that the management believes the stock is undervalued.
  • The current stock price is approximately $228.76, which is near its 50-day moving average of $232.03, suggesting stability in its recent performance.

Cons of Becton, Dickinson and Company

  • The stock has a relatively high P/E ratio of 38.00, which may indicate that the stock is overvalued compared to its earnings.
  • Insider selling has occurred, with executives selling a total of 4,984 shares recently, which could raise concerns about the company's future prospects.
  • The company has a debt-to-equity ratio of 0.69, which, while manageable, indicates that it relies on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.63 billion
P/E Ratio
36.81
Consensus Rating
Buy
Consensus Price Target
$278.29 (+25.6% Upside)
Volume
2.69 million shares
Average Volume
1.62 million shares
Today's Range
$220.24
$226.68
50-Day Range
$221.59
$249.75
52-Week Range
$218.75
$251.99
Dividend Yield
1.82%
Remove Ads
Cencora stock logo

31. Cencora NYSE:COR

$289.41 +9.90 (+3.54%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$289.33 -0.07 (-0.02%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The stock has received multiple upgrades from analysts, with the average price target currently at $280.20, indicating potential for growth.
  • Cencora, Inc. has a strong "Moderate Buy" rating from analysts, with nine out of eleven analysts recommending a buy, suggesting positive market sentiment.
  • Recent insider trading shows confidence in the company, with executives holding significant shares, although some have sold portions, indicating a strategic approach to liquidity.

Cons of Cencora

  • Insider sales have totaled 30,675 shares valued at over $8 million in the last ninety days, which may raise concerns about the executives' confidence in the company's short-term performance.
  • Despite the positive ratings, the stock has seen fluctuations, with recent sales by executives indicating potential volatility that could affect investor sentiment.
  • The decrease in ownership percentage by executives following stock sales could signal a lack of confidence in the stock's immediate future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.12 billion
P/E Ratio
41.17
Consensus Rating
Moderate Buy
Consensus Price Target
$280.20 (-3.2% Downside)
Volume
3.34 million shares
Average Volume
1.45 million shares
Today's Range
$280.03
$291.83
50-Day Range
$241.37
$289.41
52-Week Range
$214.77
$291.83
Dividend Yield
0.80%
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$15.18 +0.21 (+1.37%)
Closing price 04/3/2025 03:58 PM Eastern
Extended Trading
$15.04 -0.15 (-0.99%)
As of 06:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Recent investment by Fisher Asset Management LLC, which purchased 41,334 shares valued at approximately $547,000, indicates strong institutional interest and confidence in the company's future performance.
  • Takeda Pharmaceutical Company Limited recently reached a new 52-week high of $15.08, reflecting positive market sentiment and potential for continued growth.
  • The company reported earnings per share (EPS) of $0.42, exceeding the consensus estimate of $0.34, showcasing its ability to outperform market expectations and generate profits.

Cons of Takeda Pharmaceutical

  • The company's price-to-earnings (P/E) ratio of 37.94 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • Despite recent positive performance, the stock has a beta of 0.46, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • Takeda Pharmaceutical Company Limited has a net margin of only 4.53%, which may raise concerns about its profitability and efficiency in managing expenses relative to its revenue.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.66 billion
P/E Ratio
37.96
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
4.31 million shares
Average Volume
1.80 million shares
Today's Range
$15.09
$15.37
50-Day Range
$12.99
$15.20
52-Week Range
$12.58
$15.37
Dividend Yield
3.59%
Haleon stock logo

33. Haleon NYSE:HLN

$10.44 +0.29 (+2.81%)
Closing price 04/3/2025 03:58 PM Eastern
Extended Trading
$10.38 -0.07 (-0.66%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Haleon plc reported a revenue of $3.54 billion during the latest quarter, exceeding the consensus estimate of $3.38 billion, indicating strong financial performance and potential for growth.
  • The company has a return on equity of 14.76%, which suggests effective management and profitability relative to shareholders' equity, making it an attractive investment.
  • Haleon plc recently increased its dividend to $0.1166 per share, up from $0.05, reflecting a commitment to returning value to shareholders and a yield of 1.6%.

Cons of Haleon

  • Despite the positive revenue report, the stock has a high P/E ratio of 30.28, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Recent analyst ratings show a consensus rating of "Hold," with several brokerages downgrading their ratings, which may suggest a lack of strong bullish sentiment in the market.
  • The company has a beta of 0.25, indicating lower volatility compared to the market, which may limit potential high returns for investors seeking aggressive growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.29 billion
P/E Ratio
30.72
Consensus Rating
Hold
Consensus Price Target
$10.95 (+4.8% Upside)
Volume
13.01 million shares
Average Volume
6.60 million shares
Today's Range
$10.43
$10.58
50-Day Range
$9.40
$10.68
52-Week Range
$7.99
$10.80
Dividend Yield
1.04%
Alcon stock logo

34. Alcon NYSE:ALC

$89.56 -3.03 (-3.27%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$87.82 -1.74 (-1.95%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Alcon Inc. has shown a strong fifty-two week performance of 26.72%, indicating positive growth and investor confidence in the company's recent developments.
  • The current stock price is $91.98, which reflects a solid valuation in the market, suggesting that investors may find it a worthwhile investment opportunity.
  • Institutional ownership stands at 72.64%, which indicates that a significant portion of the company is held by institutional investors, often seen as a sign of stability and trust in the company's future.

Cons of Alcon

  • The month-to-month change in shares shorted has decreased by 7.87%, which may indicate a lack of momentum or confidence in the stock's upward trajectory.
  • Days to cover is at 4.5, suggesting that if investors wanted to cover their short positions, it would take a considerable amount of time, indicating potential volatility in the stock price.
  • Despite a strong performance, the company has a relatively high number of shares shorted at 3,160,000, which could lead to increased volatility if negative sentiment shifts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.17 billion
P/E Ratio
38.27
Consensus Rating
Moderate Buy
Consensus Price Target
$105.60 (+17.9% Upside)
Volume
1.83 million shares
Average Volume
978,066 shares
Today's Range
$89.45
$92.62
50-Day Range
$86.84
$96.95
52-Week Range
$77.54
$101.10
Dividend Yield
0.28%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$73.03 +0.98 (+1.36%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$72.50 -0.54 (-0.74%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported a strong earnings per share (EPS) of $0.59, exceeding analysts' expectations, indicating robust financial performance and potential for future growth.
  • With a market capitalization of $42.38 billion, Edwards Lifesciences Co. is a significant player in the medical technology sector, suggesting stability and potential for long-term investment.
  • The stock is currently trading around $68.76, which is below its 12-month high of $95.25, presenting a potential buying opportunity for investors looking for growth as the stock may rebound.

Cons of Edwards Lifesciences

  • The price-to-earnings (P/E) ratio of 10.34, while not excessively high, may suggest that the stock is not undervalued compared to its earnings, which could limit upside potential.
  • Insider selling has been notable, with executives selling a total of 62,553 shares recently, which may indicate a lack of confidence in the stock's short-term performance.
  • The company has a price-to-earnings-growth (PEG) ratio of 4.82, which is relatively high, suggesting that the stock may be overvalued based on its expected growth rate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.93 billion
P/E Ratio
10.48
Consensus Rating
Hold
Consensus Price Target
$79.95 (+9.5% Upside)
Volume
6.93 million shares
Average Volume
4.80 million shares
Today's Range
$70.82
$73.26
50-Day Range
$67.92
$76.23
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
Remove Ads
Veeva Systems stock logo

36. Veeva Systems NYSE:VEEV

$221.58 -4.96 (-2.19%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$219.00 -2.58 (-1.16%)
As of 06:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is approximately $232, which is near its 50-day moving average of $231.92, indicating stability and potential for growth.
  • Veeva Systems Inc. has a strong market capitalization of around $37 billion, suggesting it is a well-established player in the cloud-based software market for the life sciences industry.
  • The company has shown significant institutional interest, with 88.20% of its stock owned by institutional investors and hedge funds, indicating confidence from large financial entities.

Cons of Veeva Systems

  • The price-to-earnings (P/E) ratio is high at 56.34, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite a strong market cap, the stock has a P/E/G ratio of 1.89, suggesting that the growth rate may not justify the current price, which could deter growth-focused investors.
  • Trading volumes have been below average, with recent volumes around 977,449 shares compared to an average of 1,038,730, indicating reduced investor interest.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.05 billion
P/E Ratio
54.71
Consensus Rating
Moderate Buy
Consensus Price Target
$256.52 (+15.8% Upside)
Volume
1.65 million shares
Average Volume
1.04 million shares
Today's Range
$215.87
$225.16
50-Day Range
$218.66
$247.10
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
argenx stock logo

37. argenx NASDAQ:ARGX

$590.06 +6.44 (+1.10%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$578.20 -11.86 (-2.01%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • Recent earnings report showed a significant earnings per share (EPS) of $1.58, surpassing the consensus estimate of $0.98 by $0.60, indicating strong financial performance.
  • The stock is currently trading at $615.02, reflecting a stable market position and potential for growth, especially given its 12-month high of $678.21.
  • Analysts have a consensus rating of "Moderate Buy" with an average target price of $687.00, suggesting that there is expected upside in the stock price.

Cons of argenx

  • The company has a negative return on equity of 1.45% and a negative net margin of 2.11%, which may raise concerns about its profitability and efficiency.
  • The price-to-earnings (P/E) ratio is -698.89, indicating that the company is currently not generating profits relative to its stock price, which can be a red flag for investors.
  • Despite recent positive earnings, the company has shown volatility in its stock price, with a 12-month low of $352.77, suggesting potential risks in price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.85 billion
P/E Ratio
-670.52
Consensus Rating
Moderate Buy
Consensus Price Target
$687.00 (+16.4% Upside)
Volume
659,933 shares
Average Volume
294,082 shares
Today's Range
$585.00
$595.46
50-Day Range
$567.09
$671.74
52-Week Range
$352.77
$678.21
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$262.16 -4.67 (-1.75%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$261.68 -0.48 (-0.18%)
As of 05:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance and potential for stock price appreciation.
  • The recent price target set by HC Wainwright at $500.00 suggests significant upside potential from the current stock price, which is around $251.56, providing a compelling investment opportunity.
  • The company is focused on innovative therapeutics based on ribonucleic acid interference, positioning itself in a cutting-edge field of biopharmaceuticals that could lead to substantial market growth.

Cons of Alnylam Pharmaceuticals

  • The company reported earnings per share of ($0.65), missing the consensus estimate of ($0.62), which may raise concerns about its short-term financial performance.
  • Insider selling activity has been notable, with executives selling a significant number of shares, which could signal a lack of confidence in the company's near-term prospects.
  • Analysts project an average earnings per share of -1.7 for the current year, indicating ongoing losses that may deter potential investors looking for profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.10 billion
P/E Ratio
-120.81
Consensus Rating
Moderate Buy
Consensus Price Target
$316.25 (+20.6% Upside)
Volume
1.03 million shares
Average Volume
833,997 shares
Today's Range
$258.65
$264.65
50-Day Range
$233.07
$290.70
52-Week Range
$141.98
$304.39
Dividend Yield
N/A
IDEXX Laboratories stock logo

39. IDEXX Laboratories NASDAQ:IDXX

$410.76 -15.49 (-3.63%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$421.39 +10.63 (+2.59%)
As of 05:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price of IDEXX Laboratories, Inc. is $415.87, which may present a buying opportunity for investors looking for potential growth.
  • IDEXX Laboratories, Inc. has a strong market capitalization of $33.71 billion, indicating a robust financial position and stability in the market.
  • The company has received multiple upgrades from analysts, with a consensus price target of $533.75, suggesting potential for price appreciation.

Cons of IDEXX Laboratories

  • The stock has experienced significant insider selling, with executives reducing their holdings, which may signal concerns about the company's future performance.
  • The price-to-earnings (P/E) ratio of 38.98 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent downgrades from analysts, including a shift from "buy" to "hold," suggest that some experts are cautious about the stock's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.30 billion
P/E Ratio
38.50
Consensus Rating
Moderate Buy
Consensus Price Target
$533.75 (+29.9% Upside)
Volume
948,435 shares
Average Volume
584,866 shares
Today's Range
$407.07
$417.93
50-Day Range
$406.29
$469.04
52-Week Range
$398.50
$548.88
Dividend Yield
N/A
Cardinal Health stock logo

40. Cardinal Health NYSE:CAH

$136.96 -1.71 (-1.23%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$137.64 +0.68 (+0.49%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The stock is currently priced at $136.43, reflecting a strong performance and potential for growth, especially given its recent upgrades from multiple analysts.
  • Cardinal Health, Inc. has received a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and confidence in the company's future performance.
  • The company recently reported earnings per share (EPS) of $1.93, surpassing the consensus estimate of $1.74, which demonstrates strong financial performance and operational efficiency.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, indicating that it is not generating profit effectively from its equity, which could raise concerns about management efficiency.
  • Cardinal Health, Inc. has a relatively low net margin of 0.59%, suggesting that the company may face challenges in converting revenue into actual profit, which could impact long-term growth.
  • Despite recent upgrades, four analysts have rated the stock with a hold rating, indicating some uncertainty about its future performance compared to other investment opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.09 billion
P/E Ratio
25.55
Consensus Rating
Moderate Buy
Consensus Price Target
$140.14 (+2.3% Upside)
Volume
4.06 million shares
Average Volume
2.11 million shares
Today's Range
$135.30
$139.50
50-Day Range
$123.56
$138.82
52-Week Range
$93.17
$139.50
Dividend Yield
1.48%
Remove Ads
Agilent Technologies stock logo

41. Agilent Technologies NYSE:A

$109.63 -6.36 (-5.48%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$107.62 -2.00 (-1.83%)
As of 05:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. has received multiple upgrades from analysts, including a recent boost in target price to $165.00 by Citigroup, indicating strong confidence in the company's growth potential.
  • The company has a balanced analyst rating with seven analysts giving a "buy" rating and seven assigning a "hold" rating, suggesting a stable outlook and potential for price appreciation.
  • Agilent Technologies, Inc. operates in high-demand sectors such as life sciences and diagnostics, which are expected to continue growing, providing a solid foundation for future revenue.

Cons of Agilent Technologies

  • Bank of America recently lowered its price target from $153.00 to $150.00, which may indicate concerns about the company's short-term performance.
  • Despite the positive ratings, the presence of an equal number of "hold" ratings suggests that some analysts are cautious about the stock's immediate prospects.
  • Wells Fargo's reduction of their price objective from $157.00 to $155.00 may signal potential challenges in achieving previous growth expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.07 billion
P/E Ratio
25.20
Consensus Rating
Hold
Consensus Price Target
$150.83 (+37.6% Upside)
Volume
3.80 million shares
Average Volume
1.78 million shares
Today's Range
$109.57
$113.90
50-Day Range
$109.63
$151.75
52-Week Range
$107.28
$155.35
Dividend Yield
0.86%
GE HealthCare Technologies stock logo

42. GE HealthCare Technologies NASDAQ:GEHC

$72.00 -7.36 (-9.27%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$70.96 -1.04 (-1.44%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • Recent earnings report showed a strong performance with earnings per share of $1.45, exceeding the consensus estimate of $1.26 by $0.19, indicating robust profitability.
  • The stock is currently trading at $81.49, which may present a buying opportunity for investors looking for growth in the healthcare technology sector.
  • Analysts have a consensus rating of "Moderate Buy" for GE HealthCare Technologies Inc., with a price target averaging $98.75, suggesting potential upside for investors.

Cons of GE HealthCare Technologies

  • The company reported revenue of $5.32 billion, slightly below the consensus estimate of $5.33 billion, which may raise concerns about revenue growth.
  • Despite strong earnings, the stock has seen fluctuations, which could indicate volatility and risk for investors looking for stable returns.
  • One analyst has rated the stock with a sell rating, suggesting that there are differing opinions on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.93 billion
P/E Ratio
16.63
Consensus Rating
Moderate Buy
Consensus Price Target
$97.73 (+35.7% Upside)
Volume
9.33 million shares
Average Volume
2.95 million shares
Today's Range
$70.45
$76.59
50-Day Range
$72.00
$93.48
52-Week Range
$70.45
$94.80
Dividend Yield
0.17%
Humana stock logo

43. Humana NYSE:HUM

$264.67 -1.13 (-0.43%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$263.94 -0.73 (-0.28%)
As of 06:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. reported an EPS of ($2.16), which exceeded analysts' expectations of ($2.26) by $0.10, indicating stronger-than-expected financial performance.
  • The company has a return on equity of 11.70%, suggesting effective management in generating profits from shareholders' equity.
  • Humana Inc. recently declared a quarterly dividend of $0.885, which translates to an annualized dividend of $3.54 and a yield of 1.31%, providing a steady income stream for investors.

Cons of Humana

  • The company has a net margin of only 1.02%, which may raise concerns about profitability and operational efficiency.
  • Insider selling activity has been noted, with an insider selling 3,703 shares, which could signal a lack of confidence in the company's future performance.
  • Despite a majority of analysts rating the stock as a hold, there are only five buy ratings, indicating limited bullish sentiment among market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.94 billion
P/E Ratio
26.60
Consensus Rating
Hold
Consensus Price Target
$280.17 (+5.9% Upside)
Volume
1.81 million shares
Average Volume
1.71 million shares
Today's Range
$261.96
$274.93
50-Day Range
$249.32
$303.57
52-Week Range
$213.31
$406.46
Dividend Yield
1.34%
Centene stock logo

44. Centene NYSE:CNC

$64.37 +3.64 (+6.00%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$63.20 -1.17 (-1.81%)
As of 05:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Centene Co. reported a strong quarterly earnings result with an earnings per share (EPS) of $0.80, significantly exceeding the consensus estimate of $0.49. This indicates robust financial performance and effective management.
  • The company has a market capitalization of $29.74 billion, which reflects its substantial size and stability in the healthcare sector, making it a potentially safer investment.
  • With a current stock price of $59.96, Centene Co. is trading below the consensus price target of $79.92, suggesting potential for price appreciation as the market corrects.

Cons of Centene

  • Despite recent earnings success, the company has a relatively low net margin of 2.03%, which may indicate challenges in maintaining profitability compared to competitors.
  • Centene Co. has a debt-to-equity ratio of 0.70, which, while manageable, suggests that the company is somewhat reliant on debt financing, potentially increasing financial risk in a rising interest rate environment.
  • Recent price target reductions by analysts, such as from Truist Financial lowering their target from $89.00 to $84.00, may signal concerns about future growth prospects and market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.93 billion
P/E Ratio
10.32
Consensus Rating
Moderate Buy
Consensus Price Target
$79.92 (+24.2% Upside)
Volume
8.57 million shares
Average Volume
4.59 million shares
Today's Range
$60.64
$64.59
50-Day Range
$55.94
$65.88
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
ResMed stock logo

45. ResMed NYSE:RMD

$213.11 -9.89 (-4.44%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$214.24 +1.13 (+0.53%)
As of 05:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. reported a strong quarterly earnings result with an EPS of $2.43, surpassing analysts' expectations of $2.29. This indicates robust financial performance and potential for continued growth.
  • The company has a high return on equity of 26.17%, suggesting effective management and a strong ability to generate profits from shareholders' equity.
  • ResMed Inc. has a solid market capitalization of $32.29 billion, which reflects its stability and prominence in the medical equipment sector.

Cons of ResMed

  • Insider selling has been notable, with executives selling a total of 38,940 shares recently, which may indicate a lack of confidence in the company's short-term prospects.
  • The company has a relatively low dividend yield of 0.96%, which may not be attractive for income-focused investors looking for higher returns from dividends.
  • ResMed Inc. operates in a competitive market, and any significant changes in healthcare regulations or technology could impact its market position and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.30 billion
P/E Ratio
25.16
Consensus Rating
Moderate Buy
Consensus Price Target
$249.73 (+17.2% Upside)
Volume
1.51 million shares
Average Volume
995,215 shares
Today's Range
$211.72
$218.53
50-Day Range
$213.11
$257.63
52-Week Range
$172.19
$263.05
Dividend Yield
0.95%
Remove Ads
IQVIA stock logo

46. IQVIA NYSE:IQV

$167.62 -6.75 (-3.87%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$172.99 +5.37 (+3.20%)
As of 04:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. has a strong market capitalization of approximately $31.63 billion, indicating a robust position in the medical research sector, which can attract institutional investors.
  • The company reported a return on equity of 28.81%, showcasing its efficiency in generating profits from shareholders' equity, which is a positive indicator for potential investors.
  • Recent trading data shows that the stock price is currently at $179.40, which is near its 52-week low of $177.10, potentially offering a buying opportunity for investors looking for value.

Cons of IQVIA

  • The stock has experienced a decline of 0.3% recently, which may indicate volatility and potential challenges in maintaining its market position.
  • IQVIA's debt-to-equity ratio stands at 2.12, suggesting that the company is heavily leveraged, which can pose risks if market conditions worsen or if interest rates rise.
  • The company missed earnings expectations by $0.21 per share in its latest report, which could signal operational challenges or market pressures that may affect future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.74 billion
P/E Ratio
22.35
Consensus Rating
Moderate Buy
Consensus Price Target
$249.05 (+48.6% Upside)
Volume
2.17 million shares
Average Volume
1.31 million shares
Today's Range
$166.11
$173.89
50-Day Range
$167.62
$209.76
52-Week Range
$166.11
$252.88
Dividend Yield
N/A
Beigene stock logo

47. Beigene NASDAQ:ONC

$264.32 -10.46 (-3.81%)
As of 04/3/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Market Capitalization
$26.07 billion
P/E Ratio
-32.08
Consensus Rating
Buy
Consensus Price Target
$310.00 (+17.3% Upside)
Volume
389,916 shares
Average Volume
460,234 shares
Today's Range
$259.78
$270.00
50-Day Range
$0.00
$0.00
52-Week Range
$126.97
$287.88
Dividend Yield
N/A
DexCom stock logo

48. DexCom NASDAQ:DXCM

$61.80 -6.34 (-9.30%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$61.50 -0.29 (-0.48%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • Recent upgrades from multiple analysts, including a "strong-buy" rating from Baird R W, indicate strong market confidence in DexCom, Inc.'s future performance.
  • The average target price for DexCom, Inc. is currently set at $99.82, suggesting significant upside potential from the current stock price of $69.47.
  • DexCom, Inc. has a robust market capitalization of $27.15 billion, reflecting its strong position in the medical device industry, particularly in continuous glucose monitoring systems.

Cons of DexCom

  • Insider selling activity has been notable, with executives selling a total of 105,009 shares valued at over $8 million in the last three months, which may raise concerns about the company's future prospects.
  • The stock has recently experienced a decline of 3.7%, which could indicate volatility and potential challenges in maintaining investor confidence.
  • With a price-to-earnings (P/E) ratio of 48.58, the stock may be considered overvalued compared to industry peers, suggesting that investors might be paying a premium for future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.15 billion
P/E Ratio
43.22
Consensus Rating
Moderate Buy
Consensus Price Target
$99.82 (+61.5% Upside)
Volume
5.40 million shares
Average Volume
4.07 million shares
Today's Range
$61.48
$65.01
50-Day Range
$61.80
$90.75
52-Week Range
$61.48
$141.99
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,094.01 -78.49 (-6.69%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$1,090.70 -3.31 (-0.30%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The stock is currently trading at approximately $1,182.55, reflecting a strong market position and potential for growth.
  • Mettler-Toledo International Inc. reported earnings per share (EPS) of $12.41, exceeding analysts' expectations of $11.76, indicating robust financial performance.
  • The company has a high net margin of 22.29%, suggesting effective cost management and profitability, which can lead to higher returns for investors.

Cons of Mettler-Toledo International

  • The company has a negative return on equity of 591.54%, which may raise concerns about its ability to generate profit from shareholders' equity.
  • Despite strong earnings, the stock has a high price-to-earnings (P/E) ratio of 29.18, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • The stock has experienced volatility, with a beta of 1.15, indicating that it may be more volatile than the overall market, which could pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$22.80 billion
P/E Ratio
26.99
Consensus Rating
Hold
Consensus Price Target
$1,380.50 (+26.2% Upside)
Volume
227,881 shares
Average Volume
131,707 shares
Today's Range
$1,087.72
$1,150.35
50-Day Range
$1,094.01
$1,390.00
52-Week Range
$1,087.72
$1,546.93
Dividend Yield
N/A
Zimmer Biomet stock logo

50. Zimmer Biomet NYSE:ZBH

$112.72 +0.22 (+0.19%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$112.86 +0.14 (+0.13%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. More about Zimmer Biomet

Pros of Zimmer Biomet

  • The company has reported a net margin of 11.77%, indicating efficient management of expenses relative to revenue, which can lead to higher profitability for shareholders.
  • Zimmer Biomet Holdings, Inc. has a return on equity of 12.99%, suggesting that the company is effective at generating profits from its equity, which is a positive sign for potential investors.
  • With a current stock price of $112.41, the stock has shown resilience and potential for growth, especially considering its twelve-month high of $131.61.

Cons of Zimmer Biomet

  • The stock has a price-to-earnings (P/E) ratio of 25.26, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Zimmer Biomet Holdings, Inc. has a debt-to-equity ratio of 0.43, which, while manageable, indicates that the company does carry some debt, posing a risk if market conditions change.
  • The average rating for the stock is "Hold," which may imply that analysts are not overly optimistic about its short-term performance, suggesting caution for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$22.44 billion
P/E Ratio
25.33
Consensus Rating
Hold
Consensus Price Target
$124.15 (+10.1% Upside)
Volume
2.92 million shares
Average Volume
1.57 million shares
Today's Range
$111.41
$114.44
50-Day Range
$98.98
$113.33
52-Week Range
$97.69
$130.89
Dividend Yield
0.86%
Remove Ads